Option Care Health, Inc. (OPCH)
| Market Cap | 4.66B +5.0% |
| Revenue (ttm) | 5.69B +5.9% |
| Net Income | 209.58M -0.8% |
| EPS | 1.32 +4.7% |
| Shares Out | 149.79M |
| PE Ratio | 23.51 |
| Forward PE | 19.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,267,123 |
| Open | 31.05 |
| Previous Close | 31.05 |
| Day's Range | 31.03 - 31.08 |
| 52-Week Range | 18.01 - 36.80 |
| Beta | 0.58 |
| Analysts | Hold |
| Price Target | 29.53 (-5.0%) |
| Earnings Date | Nov 4, 2026 |
About OPCH
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arth... [Read more]
Financial Performance
In 2025, Option Care Health's revenue was $5.65 billion, an increase of 13.03% compared to the previous year's $5.00 billion. Earnings were $207.59 million, a decrease of -2.00%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for OPCH stock is "Hold." The 12-month stock price target is $29.53, which is a decrease of -5.00% from the latest price.
News
Option Care Health downgraded to Neutral from Buy at UBS
UBS downgraded Option Care Health (OPCH) to Neutral from Buy with a price target of $32.05, down from $39, after CD&R and McKesson (MCK) entered into an agreement to acquire…
Option Care Health downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Option Care Health (OPCH) to Neutral from Overweight with a $33 price target after CD&R and McKesson (MCK) entered into an agreement to acquire the company for $32.05…
Option Care Health downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Option Care Health (OPCH) to Market Perform from Outperform without a price target after the company entered into a definitive agreement to be acquired by...
Option Care Health downgraded to Hold from Buy at Truist
Truist downgraded Option Care Health (OPCH) to Hold from Buy with a $32.05 price target after CD&R and McKesson (MCK) entered into an agreement to acquire the company for $32.05…
Halper Sadeh LLC is Investigating Whether PTC and OPCH are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Option Care Health downgraded to Market Perform from Outperform at Citizens
Citizens analyst Constantine Davides downgraded Option Care Health (OPCH) to Market Perform from Outperform after CD&R and McKesson (MCK) entered into an agreement to acquire the company for $32.05 pe...
Option Care Health downgraded to Hold from Buy at Jefferies
Jefferies downgraded Option Care Health (OPCH) to Hold from Buy with a price target of $32.05, up from $28, after CD&R and McKesson (MCK) entered into an agreement to acquire…
Option Care Health downgraded to Market Perform from Outperform at William Blair
William Blair analyst Matt Larew downgraded Option Care Health (OPCH) to Market Perform from Outperform after CD&R and McKesson (MCK) entered into an agreement to acquire the company for $32.05…
Option Care Health rises 32.9%
Option Care Health (OPCH) is up 32.9%, or $7.68 to $31.05.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)
BALA CYNWYD, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Option Care Health rises 32.9%
Option Care Health (OPCH) is up 32.9%, or $7.69 to $31.05.
Option Care Health withdraws previously disclosed guidance
Option Care Health (OPCH) expects to release its financial results for the third quarter ended September 30, 2026, on November 4, 2026. Given the transaction announcement, Option Care Health will…
McKesson, CD&R to acquire Option Care Health for $32.05 per share
CD&R, McKesson Corporation (MCK) and Option Care Health, Inc. (OPCH) announced that they have entered into a definitive agreement, under which CD&R and McKesson will acquire Option Care Health, an…
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice on Tuesday agreed to take infusion therapy provider Option Care Health private in a deal worth about $5.8 billion including ...
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
NEW YORK & IRVING, Texas & BANNOCKBURN, Ill.--(BUSINESS WIRE)--CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today t...
Option Care Health Proxy statement: Proxy filing
Option Care Health filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
Option Care Health Proxy statement: Proxy filing
Option Care Health filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
Morgan Stanley would like McKesson deal for Option Care Health
After the Financial Times reported that McKesson (MCK) and private equity firm CD&R are potentially nearing a deal to buy Option Care Health (OPCH) for about $5B, with McKesson acquiring…
Closing Bell Movers: Option Care Health up over 20% on takeover interest
Broad-based strength in the mega-cap tech space – in spite of continued upward pressure in Treasury yields – helped the Nasdaq Composite to fresh record highs on Monday and also…
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice are nearing a deal to acquire infusion services provider Option Care Health in a transaction valued at more than $5 billion ...
McKesson, PE partner near deal to acquire Option Care Health, FT reports
Option Care Health (OPCH) is in advanced talks to sell itself after receiving a joint bid from McKesson (MCK) and private equity firm Clayton Dubilier & Rice in a deal…
Option Care Health up 24% after FT report on McKesson takeover interest
Shares of Option Care Health (OPCH) are up 24% to $28.89 in after-hours trading.
McKesson, CD&R near deal to buy Option Care Health, FT says
16:04 EDT McKesson (MCK), CD&R near deal to buy Option Care Health (OPCH), FT says
Option Care Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Momentum has stabilized with growth in acute and specialty therapies, supported by a diversified portfolio and strong hospital partnerships. Biosimilar competition and new rare therapies are expected to drive future growth, while regulatory changes and capital allocation remain focused on expanding access and operational efficiency.
Option Care Health to Participate in Upcoming Investor Conferences
BANNOCKBURN, Ill., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion serv...